Effect of asoprisnil on uterine proliferation markers and endometrial expression of the tumour suppressor gene, PTEN

Human Reproduction

Volumn 24, Issue 5, 2009, Pages 1036-1044

  Wilkens, J ^a   Williams, A R W ^b   Chwalisz, K ^c   Han, C ^d   Cameron, I T ^e   Critchley, H O D ^a  

^a UNIVERSITY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c ABBOTT LABORATORIES   (United States)

^d TAKEDA PHARMACEUTICALS   (United States)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

Asoprisnil; Phosphatase and tensin homologue; Proliferation; Uterine tissues

Indexed keywords

ASOPRISNIL; BIOLOGICAL MARKER; ESTROGEN; HISTONE; HISTONE H3; KI 67 ANTIGEN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLACEBO; PROGESTERONE;

ADULT; ARTICLE; CELL COUNT; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFECT; ENDOMETRIUM CELL; FEMALE; FOLLICULAR PHASE; GENE EXPRESSION; HORMONE BLOOD LEVEL; HUMAN; HUMAN CELL; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; IMMUNOLOCALIZATION; MULTICENTER STUDY; MYOMETRIUM; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SECRETORY CELL; STAINING; STEREOLOGY; STROMA CELL; TREATMENT DURATION; TUMOR SUPPRESSOR GENE; UTERUS MYOMA;

EID: 67449168270     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/den494     Document Type: Article

References (35)

1. Aasmundstad TA, Haugen OA, Johannesen E, Hoe AL, Kvinnsland S. Oestrogen receptor analysis: correlation between enzyme immunoassay and immunohistochemical methods. J Clin Pathol 1992; 45:125-129.
2. Baird DT, Brown A, Critchley HO, Williams AR, Lin S, Cheng L Effect of long term treatment with low dose mifepristone on the endometrium. Hum Reprod 2003;18:61-68.
3. Brenner RM, Slayden OD. Progesterone receptor antagonists and the endometrial antiproliferative effect. Semin Reprod Med 2005;23:74-81.
4. Brenner RM, Slayden OD, Critchley HO. Anti-proliferative effects of progesterone antagonists in the primate endometrium: a potential role for the androgen receptor. Reproduction 2002;124:167-172.
5. Brenner RM, Slayden OD, Rodgers WH, Critchley HO, Carroll R, Nie XJ, Mah K. Immunocytochemical assessment of mitotic activity with an antibody to phosphorylated histone H3 in the macaque and human endometrium. Hum Reprod 2003:18:1185-1193.
6. Brenner RM, Slayden OD, Garg RC, Chwalisz K. Asoprisnil suppresses endometrial proliferation in cynomolgus macaques. J Soc Gynecol Investig 2005:12: Abstract 384.
7. Bullwinkel J, Baron Luhr B, Ludemann A, Wohlenberg C, Gerdes J, Scholzen T. Ki-67 protein is associated with ribosomal RNA transcription in quiescent and proliferating cells. J Cell Physiol 2006; 206:624-635.
8. Chen W, Ohara N, Wang J, Xu Q, Liu J, Morikawa A, Sasaki H, Yoshida S, Demanno DA, Chwalisz K et al. A novel selective progesterone receptor modulator asoprisnil (J867) inhibits proliferation and induces apoptosis in cultured human uterine leiomyoma cells in the absence of comparable effects on myometrial cells. J Clin Endocrinol Metab 2006:91:1296-1304.
9. Chwalisz K, Brenner RM, Fuhrmann UU, Hess Stumpp H, Elger W. Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium. Steroids 2000:65:741-751.
10. Chwalisz K, Elger W, Stickler T, Mattia Goldberg C, Larsen L. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. Hum Reprod 2005a;20:1090-1099.
11. Chwalisz K, Perez MC, Demanno D, Winkel C, Schubert G, Elger W. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005b; 26:423-438.
12. Chwalisz K, Garg R, Brenner R, Slayden O, Winkel C, Elger W. Role of nonhuman primate models in the discovery and clinical development of selective progesterone receptor modulators (SPRMs). Reprod Biol Endocrinol 2006;4(Suppl 1):S8.
13. Chwalisz K, Larsen L, Mattia Goldberg C, Edmonds A, Elger W, Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator, in women with uterine leiomyomata. Fertil Steril 2007;87:1399-1412.
14. Chwalisz K, Williams A, Brenner R. Endometrial effects of selective progesterone receptor modulators. In: Aplin J, Fazleabas A, Glasser S, Giudice L (eds). The Endometrium Molecular, Cellular, and Clinical Perspectives. London: Informa Healthcare, 2008, 613-622.
15. Daikoku T, Hirota Y, Tranguch S, Joshi AR, DeMayo FJ, Lydon JP, Ellenson LH, Dey SK. Conditional loss of uterine Pten unfailingly and rapidly induces endometrial cancer in mice. Cancer Res 2008:68:5619-5627.
16. DeManno D, Elger W, Garg R, Lee R, Schneider B, Hess Stumpp H, Schubert G, Chwalisz K. Asoprisnil (J867): a selective progesterone receptor modulator for gynecological therapy. Steroids 2003;68: 1019-1032.
17. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol 2003; 101: 243-250.
18. Endl E, Gerdes J. The Ki-67 protein: fascinating forms and an unknown function. Exp Cell Res 2000:257:231-237.
19. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation associated human nuclear antigen defined by the monoclonal antibody Ki 67. J Immunol 1984; 133:1710-1715.
20. Kirkwood B, Sterne J. Calculation of required sample size. Essential Medical Statistics. Oxford: Blackwell Science Ltd, 2003, 413-423.
21. Mahood IK, Hallmark N, McKinnell C, Walker M, Fisher JS, Sharpe RM. Abnormal Leydig cell aggregation in the fetal testis of rats exposed to di-(n-butyl)-phthalate and its possible role in testicular dysgenesis. Endocrinology 2005;146:613-623.
22. Mutter GL. Pten, a protean tumor suppressor. Am J Pathol 2001; 158:1895-1898.
23. Mutter GL, Ferenczy A. Anatomy and histology of the uterine corpus. In: Kurman R (ed). Blaustein's Pathology of the Female Genital Tract. New York: Springer, 2002, 383-419.
24. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, Lees JA, Weng LP, Eng C. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000:92:924-930.
25. Mutter GL, Ince TA, Baak JP, Kust GA, Zhou XP, Eng C. Molecular identification of latent precancers in histologically normal endometrium. Cancer Res 2001;61:4311-4314.
26. Orbo A, Rise CE, Mutter GL Regression of latent endometrial precancers by progestin infiltrated intrauterine device. Cancer Res 2006;66:5613-5617.
27. Reinsch RC, Murphy AA, Morales AJ, Yen SS. The effects of RU 486 and leuprolide acetate on uterine artery blood flow in the fibroid uterus: a prospective, randomized study. Am J Obstet Gynecol 1994; 170:1623-1627. discussion 1627-1628.
28. Schubert G, Elger W, Kaufmann G, Schneider B, Reddersen G, Chwalisz K. Discovery, chemistry, and reproductive pharmacology of asoprisnil and related II beta-benzaldoxime substituted selective progesterone receptor modulators (SPRMs). Semin Reprod Med 2005:23:58-73.
29. Slayden OD, Brenner RM. RU 486 action after estrogen priming in the endometrium and oviducts of rhesus monkeys (Macaca mulatta). J Clin Endocrinol Metab 1994:78:440-448.
30. Slayden OD, Zelinski-Wooten MB, Chwalisz K, Stouffer RL, Brenner RM. Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: morphometric assessment of the uterus and oviduct. Hum Reprod 1998;13:269-277.
31. Slayden OD, Brenner RM. Flutamide counteracts the antiproliferative effects of antiprogestins in the primate endometrium. J Clin Endocrinol Metab 2003:88:946-949.
32. Wllkens J, Chwalisz K, Han C, Walker J, Cameron IT, Ingamells S, Lawrence A, Lumsden MA, Hapangama D, Williams AR et al. Effects of the selective progesterone receptor modulator asoprisnil on uterine artery blood flow, ovarian activity and clinical symptoms in patients with uterine leiomyomata scheduled for hysterectomy. J Clin Endocrinol Metab 2008;93:4664-4671.
33. Williams AR, Critchley HO, Osei J, Ingamells S, Cameron IT, Han C, Chwalisz K. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. Hum Reprod 2007:22:1696-1704.
34. Wolf JP, Hsiu JG, Anderson TL, Ulmann A, Baulieu EE, Hodgen GD. Noncompetitive antiestrogenic effect of RU 486 In blocking the estrogen stimulated luteinizing hormone surge and the proliferative action of estradiol on endometrium in castrate monkeys. Fertil Steril 1989:52:1055- 1060.
35. Zheng W, Baker HE, Mutter GL Involution of PTEN-null endometrial glands with progestin therapy. Gynecol Oncol 2004:92:1008-1013.